Rate of Pharmacotherapy for Tobacco Smoking Cessation in Patients With New Peripheral Artery Disease | Synapse
February 25, 2026Open Access
Rate of Pharmacotherapy for Tobacco Smoking Cessation in Patients With New Peripheral Artery Disease
Key Points
This study aims to explore how often patients with newly diagnosed peripheral artery disease use varenicline for quitting smoking.
Conducted a cross-sectional analysis using US insurance claims data
Focused on adults with newly diagnosed peripheral artery disease
Assessed the rate of varenicline prescriptions for smoking cessation
Identified the percentage of patients using varenicline for smoking cessation
Showed a potential gap in pharmacotherapy rates among patients
Highlighted variability in treatment adherence in the target population
Abstract
This cross-sectional study uses US insurance claims data to examine the rate of varenicline use for tobacco smoking cessation among adults with newly diagnosed peripheral artery disease.